StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'
April 27, 2026 10:48 AM
TD Cowen analyst Joseph Thome reiterated a Buy rating on Intellia Therapeutics ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Intellia Therapeutics (NTLA) PT Raised to $13 at Baird
April 27, 2026 10:15 AM
Intellia Therapeutics (NTLA) PT Raised to $20 at BofA Securities
April 27, 2026 10:10 AM
Form 8-K Intellia Therapeutics, For: Apr 27
April 27, 2026 9:14 AM
Intellia begins rolling FDA submission for gene editing therapy
April 27, 2026 7:03 AM
Intellia reports positive phase 3 results for gene editing HAE treatment
April 27, 2026 7:00 AM
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
April 27, 2026 7:00 AM
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
April 27, 2026 7:00 AM
Intellia to report Phase 3 CRISPR gene editing trial data April 27
April 24, 2026 4:05 PM
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
April 24, 2026 4:05 PM
